ZILBRYSQ 16.6 mg, solution for injection in a pre-filled syringe 7 syringes of 0.416 ml
Active ingredients: Zilucoplan, Zilucoplan sodium
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injection7 syringes of 0.416 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ZILBRYSQ 16,6 mg, solution injectable en seringue préremplie
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 7 seringues préremplies en verre avec dispositif de sécurité de 0,416 mL
- Marketing authorisation holder
- UCB PHARMA BELGIQUE
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 1 Mar 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
68906518CIP73028089CIP133400930280898Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ZILUCOPLAN SODIQUEsolution | — | SA |
| ZILUCOPLANsolution | 16,6 mg · une seringue préremplie | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.